Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL21975

CCCC[N+](CCCC)(CCCC)CCCC.[F-].[F-].[F-].[H+].[H+]

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 4/20 0.86
SLC22A2 O15244 1/20 0.73
TSHR P16473 2/20 0.65
ALDH1A1 P00352 1/20 0.65
TP53 P04637 1/20 0.65
CYP3A4 P08684 1/20 0.65
ALOX15 P16050 1/20 0.65
ALOX12 P18054 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HIF1A Q16665 1/20 0.65
HSD17B10 Q99714 1/20 0.65
DNM1 Q05193 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL2123749 1.00 SLC22A1 (0.86) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL4494449 0.97 SLC22A1 (0.80) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL1444822 0.97 SLC22A1 (0.80) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL226110 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL2580744 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL5144255 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL466 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL792649 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL8840674 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL633811 0.96 SLC22A1 (0.92) SLC22A1SLC22A2TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387315-A1 Dental Varnishes Based On Cationic Polymer Dispersions IVOCLAR VIVADENT AG (LI) 2025-12-25 US claimed
EP-3513777-B1 METHOD FOR THE REMINERALISATION OF TEETH IVOCLAR VIVADENT AG (LI) 2023-10-04 EP claimed
US-11712405-B2 Method for the remineralization of teeth IVOCLAR VIVADENT AG (LI) 2023-08-01 US claimed
CN-115010903-A Silane terminated resin based on mercapto click reaction and synthetic method thereof 郑州恩德富新材料科技有限公司 2022-09-06 CN claimed
US-20220192939-A1 Composition For The Remineralization Of Teeth IVOCLAR VIVADENT AG (LI) 2022-06-23 US claimed
EP-4014948-A1 COMPOSITION FOR THE REMINERALISATION OF TEETH Ivoclar Vivadent AG (LI) 2022-06-22 EP claimed
CN-112055712-A Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2020-12-08 CN claimed
CN-109037774-B Crosslinked polymer electrolyte suitable for lithium secondary battery and preparation method thereof 哈尔滨工业大学无锡新材料研究院 2020-10-09 CN claimed
US-20190224082-A1 METHOD FOR THE REMINERALIZATION OF TEETH IVOCLAR VIVADENT AG (LI) 2019-07-25 US claimed
US-7648742-B2 Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media MERCK PATENT GMBH (DE) 2010-01-19 US claimed
US-20090104144-A1 Gypsum board with a fluorine-containing antifungal agent QUICK-MED TECHNOLOGIES, INC. (US) 2009-04-23 US claimed
US-20080071097-A1 Difluorosubstituted Heterocyclic Compounds and the Use Thereof in the Form of Components in Liquid Crystalline Media MERCK PATENT GMBH (DE) 2008-03-20 US claimed
WO-2006012965-A1 DIFLUOROSUBSTITUTED HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN THE FORM OF COMPONENTS IN LIQUID CRYSTALLINE MEDIA MERCK PATENT GMBH (DE) 2006-02-09 WO claimed
US-6773822-B2 ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. TEMPLE-INLAND FOREST PRODUCTS CORPORATION 2004-08-10 US claimed
EP-0189448-B1 AGENT FOR THE FLUORIDATION OF ORGANIC COMPOUNDS PARTICULARLY ACETYLENIC COMPOUNDS, PREPARATION PROCESS THEREOF AND UTILIZATION THEREOF IN NUCLEOPHILIC SUBSTITUTION OR ADDITION REACTIONS UNIVERSITE D'ANGERS (FR) 1989-01-25 EP claimed
JP-11286465-A None JP disclosed
JP-4264041-A None JP disclosed
JP-H04264041-A PRODUCTION OF DIFLUOROMETHYLENE COMPOUND SAGAMI CHEM RES CENTER 1992-09-18 JP disclosed
US-5011944-A Substituted α-pyrones CIBA-GEIGY CORPORATION (US) 1991-04-30 US disclosed
EP-0344113-A2 Substituted alpha-pyrones and naphthoquinones CIBA-GEIGY AG (CH) 1989-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071097-A1 Difluorosubstituted Heterocyclic Compounds and the Use Thereof in the Form of Components in Liquid Crystalline Media C1S, CCND3, CCND2 SLC22A1 2865/4885SLC22A2 2726/4885TSHR 2502/4885
US-20250387315-A1 Dental Varnishes Based On Cationic Polymer Dispersions TUBA3C, DNMT1, TUBA1A SLC22A1 1212/4885SLC22A2 1011/4885TSHR 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.